ImpriMed
Mountain View
About ImpriMed
ImpriMed is a company that creates individualized drug response prediction technology to help veterinarians fight lymphoma. The company's technology provides precision medicine techniques that allow veterinary oncologists to find appropriate anticancer drugs by developing a patient-derived database for pet cancer treatment that can eventually be translated into human cancer care, allowing doctors to decide on a final treatment regimen based on a data-driven prediction of response success in each individual patient's body.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $34.7M
- Funding stage: Early Stage Venture
- Last round: Series A (Nov 2023)
- Website: imprimedicine.com
- Phone: +82 650-521-0165
Industries & Categories
Artificial Intelligence (AI), Biotechnology, Machine Learning, Medical, Veterinary
Social Profiles
Canonical: https://fsome.com/organization/imprimed-69915 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.